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S844 Journal of Thoracic Oncology Vol. 12 No. 1Scondition of co-cultivation with macrophages from mice
without therapy. TAs+PO244 therapy decreased popula-
tion of LLC cells in proliferative pool (G2/M+S phase) to
40%,whereas control rateswere65%and60% inLLCcells
without co-culture and LLC cells with macrophage co-cul-
ture from mice without therapy, respectively. As the ad-
hesive potential inversely correlates with cell ability to
migrating, the in vitro data indicated that migration and
tumor inﬁltration can be activate when tumor growing in
vivo. We have shown it in combined therapeutic scheme
application of TA and PO244 on LLC. Monotherapy by TA
stimulates tumor inﬁltration by lymphocytes insigniﬁ-
cantly, whereas in combined therapy with PO244 this
parameter is increased 2.4 times (p<0.05).
Conclusion: Cytotoxic/cytostatic inﬂuence, which was
expressed in increasing of apoptotic level anddecreasing of
cell population of proliferative pool was deﬁned after co-
cultivation of macrophages from LLC-bearing mice treated
by TAs+PO244with primary LLC culture. This effect can be
one of the possible mechanisms of TAs+PO244 impact on
the lung cancer.
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Background: Protein arginine methyltransferase 5
(PRMT5), a member of the protein arginine methyl-
transferase family, has important regulatory function in
manycellular processes throughepigenetic controlof target
gene expression. Because of its overexpression in a number
of human cancers and its essential role in cell proliferation,
transformation and cell cycle progression, PRMT5 has been
recently proposed to function as an oncoprotein in cancer
cells. In this study, we explore prognostic and predictive
valueofPRMT5expression in lung cancer. Impact of PRMT5
inhibition in the setting of radiation therapy and platin-
based chemotherapy was investigated.
Methods: PRMT5 expression levels in lung tumors as
well as their paired normal tissue obtained from TCGApublic databases were compared. The impact of PRMT5
expression on lung cancer patient survival was investi-
gated by using “Director’s challenge Consortium for the
Molecular Classiﬁcation of Lung Adenocarcoma” and
JBR10 datasets. SiRNA designed to target PRMT5 was
used to transiently knockdown (KD) PRMT5 expression
in several lung cancer cell lines. Clonogenic survival as-
says of lung cancer cell lines with increasing doses of
cisplatin or radiation were performed in cells with
normal endogenous PRMT5 expression or in cells after
siRNA knockdown. Impact of PRMT5 knockdown in cell
cycle, apoptosis, DNA damage response was investigated
through cell cycle analysis, Annexin/PI ﬂow cytometry,
ɣH2A foci measurements in lung cancer cells with
normal or reduced PRMT5 expression.
Results: PRMT5 expression is signiﬁcant higher in lung
tumors compared to parired normal tissue in TCGA
datasets (LUAD and LUSC) with p value 0.0001. Pa-
tients with high PRMT5 expression portend lower
overall survival at 3 years (p¼0.02) from director’s
challenge lung cancer study. Patients with low PRMT5
expression had signiﬁcantly better DFS at 5 years
(p¼0.3) if they received cisplatin while patients with
high PRMT5 expression did not beneﬁt from cisplatin
treatment (p¼0.7). In several lung cancer cell lines, we
observed >90% PRMT5 KD in transiently transfected
cells at 48 h and 72 h post transfection as veriﬁed by
western blot analysis. This inhibition of PRMT5 activity
achieved by transient KD lead to a signiﬁcant decrease in
colony survival after radiation and cisplatin. There is an
increase of cell population in G1 arrest in PRMT5 tran-
sient KD cells.
Conclusion: High PRMT5 expression is associated with
worse survival in lung cancer patients. Inhibition of
PRMT5 in lung cancer cells results in sensitization to
cisplatin and radiotherapy,
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Background: A subset of NSCLCs (approx. 5%), present
alterations in ALK gene. This produces abnormal ALK
proteins that induce cells to grow and spread. Different
generation of ALK inhibitors are available for targeted
therapy and their indication depends on the detection of
ALK alterations in the tissue. Thus, it is mandatory to
develop new techniques that allow us to demonstrate
ALK alterations in peripheral blood. The purpose of this
study is to analyze the feasibility to determine ALK al-
terations in exosomes (Exo-ALK) in NSCLC patients and
determine the sensitivity and speciﬁcity of the technique.
Methods: This study is performed in blind in a cohort 19
NSCLC with and without known alterations of ALK in tu-
moral tissue. ALK-positive tissue samples were identiﬁed
by FISH or IHQ and patients were included independently
of stage and time of disease. Exosomal RNA is isolated by
exoRNeasy Serum/Plasma (Qiagen) and retrotranscripted
by ProtoScript II First Strand cDNA Synthesis kit. The ALK
gene present in the exosomes was determined by NGS and
bioinformatic analysis byOncoDNA. Samples anddata from
patients included in the study were provided by the Bio-
bank of the University of Navarra and were processed
following standard operating procedures approved by the
Ethical and Scientiﬁc Committees, were provided also by
UZA Biobank and by the University of Naples Federico II.
Results: The analyzed samples have been 16 ALK-EML4
tissue positive patients and 3 ALK-EML4 tissue negative,
deﬁned in this casebyFISH.After analysis,wehavebeenable
to detect 9 positive ALK-EML4 patients, 8 negative samples
and 2 samples where the RNAwas degraded. Looking at the
clinical data, the 9 positive samples detected in the exosomal
RNA were positive also for ALK-EML4 translocation in the
tissue, and comparing the 8 negative samples, 3 were tissue
negative and 5 tissue positive. These data show a speciﬁcity
of 64% and a speciﬁcity of 100%. No correlation has been
found comparing naïve patients with treated patients.
Conclusion: Exosomes are raising as one of the most
promising tools to understand the tumor due to their
stability in the blood and their similarity to the cells of
origin. Our preliminary results show a high speciﬁcity andsensitivity for a proof of concept analysis. Further studies
with a bigger number of patients and a cross validation
analysis are required, but as we represent in this abstract,
exosomes can represent an important tool for the clinical
management of this speciﬁc NSCLC population.
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Background: The molecular composition NSCLC is het-
erogeneous and clinically manifested as differential
therapeutic responsiveness. It is increasingly appreci-
ated that changes in high order chromatin (HOC) struc-
ture may play an important role in controlling gene
expression and may be one of the fundamental events in
carcinogenesis. However, while several HOC regulators
are altered in lung cancer (e.g. Arid1a) from the cancer
genome atlas work (TCGA), these occur in a minority of
tumors suggesting involvement of other modulators.
Recently, SA-1 (Stag-1), a member of the cohesin family,
has been shown to be a HOC regulator in cancer via
controlling chromatin looping and hence gene expres-
sion. Since no previous reports on cohesin in lung cancer,
we therefore, focused on the role of SA-1 in NSCLC.
Methods: We performed immunohistochemical analysis
(IHC) of 190 cancers and compared to benign tissue
through standard techniques. We also extracted SA-1
data from the TCGA databases (Nature 2012 & 2014).
Results: SA-1 was markedly (w2-3 fold) overexpressed
in all types of NSCLC (p<0.01) versus benign tissue
(Figure 1). This increase was striking at stage 1 NSCLCs
with minimal further increase noted at higher stages.
TCGA data demonstrated ampliﬁcation/mutation in
w17% of squamous but only 3% of adenocarcinomas.
This suggested that epigenetic regulations was
paramount. Kaplan-Meier analysis showed major impact
of SA-1 alterations on survival. For instance, in squamous
cancers, median disease-free survival with versuswithout
SA-1 ampliﬁcation was 8 vs 38 months, respectively.
